Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatry Res. 2014 Aug 30;218(3):353-5. doi: 10.1016/j.psychres.2014.04.030. Epub 2014 Apr 28.

Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression.

Author information

1
Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
2
Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: psy@med.niigata-u.ac.jp.

Abstract

We investigated the association between remission of depressive symptoms in fluvoxamine treatment and catechol-O-methyltransferase (COMT) gene. Sixteen SNPs in the COMT gene were investigated in 123 outpatients with major depression. Three single nucleotide polymorphisms located in the 5' region were associated with remission in fluvoxamine-treated outpatients with moderate to severe depression.

KEYWORDS:

COMT; Depression; Fluvoxamine

PMID:
24814141
DOI:
10.1016/j.psychres.2014.04.030
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center